NCT01061775View on ClinicalTrials.gov

Effects of Exenatide on Hypothalamic Obesity

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

July 31, 2013

Study Completion Date

March 15, 2019

Conditions
Hypothalamic Obesity
Interventions
DRUG

Exenatide

5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.

Trial Locations (2)

55102

Children's Hospitals & Clincis of Minnesota, Saint Paul

92868

Children's Hospital of Orange County, Orange

Sponsors
All Listed Sponsors
collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

lead

Children's Hospitals and Clinics of Minnesota

OTHER